Eaton Vance Management Incyte Corp Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Incyte Corp stock. As of the latest transaction made, Eaton Vance Management holds 184,963 shares of INCY stock, worth $13.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

184,963

Previous 184,648 0.17%

Holding current value

$13.6 Million

Previous $14 Million 12.13%

% of portfolio

0.02%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $20,846 - $26,100	315 Added 0.17%	184,963 $12.3 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $917,651 - $1.15 Million	-13,866 Reduced 6.98%	184,648 $14 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $3.8 Million - $4.59 Million	57,610 Added 40.89%	198,514 $15.8 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $5.8 Million - $6.79 Million	-91,629 Reduced 39.4%	140,904 $10.2 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $83,502 - $102,168	-1,216 Reduced 0.52%	232,533 $15.9 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $1.26 Million - $1.39 Million	-15,832 Reduced 6.34%	233,749 $19.7 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $646,322 - $854,451	8,502 Added 3.53%	249,581 $20.3 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $2.15 Million - $2.6 Million	26,603 Added 12.4%	241,079 $21 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $7.38 Million - $9.52 Million	-86,801 Reduced 28.81%	214,476 $19.2 Million
Q2 2020 Nov 20, 2020	BUY	$74.18 - $108.93 $16,838 - $24,727	227 Added 0.08%	301,277 $31.3 Million
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $5.61 Million - $8.23 Million	-75,579 Reduced 20.07%	301,050 $31.3 Million
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $11.3 Million - $15.3 Million	178,295 Added 89.9%	376,629 $27.6 Million
Q4 2019 Feb 11, 2020	SELL	$73.04 - $95.72 $1.06 Million - $1.39 Million	-14,506 Reduced 6.82%	198,334 $17.3 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $2.23 Million - $2.65 Million	-30,665 Reduced 12.59%	212,840 $15.8 Million
Q2 2019 Aug 16, 2019	SELL	$73.52 - $88.7 $3.24 Million - $3.91 Million	-44,073 Reduced 15.33%	243,505 $20.7 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $5.49 Million - $7.62 Million	86,390 Added 42.94%	287,578 $24.7 Million
Q4 2018 Feb 07, 2019	SELL	$58.5 - $69.94 $10.9 Million - $13 Million	-185,993 Reduced 48.04%	201,188 $12.8 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $13 Million - $15.6 Million	210,110 Added 118.66%	387,181 $26.7 Million
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $13.1 Million - $18 Million	-214,635 Reduced 54.79%	177,071 $11.9 Million
Q1 2018 May 07, 2018	SELL	$83.06 - $100.98 $1.89 Million - $2.3 Million	-22,742 Reduced 5.49%	391,706 $32.6 Million
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $5.82 Million - $7.25 Million	62,171 Added 17.65%	414,448 $39.3 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $38.5 Million - $48.7 Million	352,277	352,277 $41.1 Million

Others Institutions Holding INCY

# of Institutions

708

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Incyte Corp Transaction History